Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients
The aim of the study is to evaluate the effect of oral isotretinoin on SerumYKL40 in acne vulgaris patients.
Arms and Interventions
|Active Comparator: Isotretinoin group
Patients will be treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum YKL40 will be assessed before and after treatment
Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
|No Intervention: Control group
Assessment of serum YKL40 in healthy individuals
Primary Outcome Measures
- Evaluation of the effect of oral isotretinoin on SerumYKL40 in acne vulgaris patients. [3 months]
Assessment in serum level YKL40 level in acne vulgaris patients after isotretinoin therapy with assesment of its level before starting therapy for detecting changes in serum YKL40 and effect of isotretinoin therapy on it.
Healthy persons of both sexes with moderate and severe acne.
Age above 14 years.
Pregnant and lactating women, immunocompromised patients.
History of chronic liver disease, hyperlipidemia, non-inflammatory acne conditions, , history of neurologic disorders, history of neoplastic disorders, and history of cardiac disease.
History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.
Cases with known hypersensitivity reaction to isotretinoin.
Contacts and Locations
Sponsors and Collaborators
- Alshimaa Abbas Mohamed Ebrahim
Study Documents (Full-Text)None provided.